AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Aspira Women's Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.22−0.01 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $9.91M
- P/E (TTM)
- –
- Dividend yield
- –
Aspira Women's Health statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Market Cap | $10.45M | $166.30M |
| Enterprise Value | $11.67M | $88.19M |
| PS Ratio | 61.45 | 3.65 |
Enterprise value
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| EV / Sales | 68.67 | 2.51 |
Income (trailing twelve months)
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Revenue | $170.00K | $58.34M |
| Gross Profit | $5.02M | $105.94M |
| Operating Income | -$6.90M | -$21.40M |
| Net Income | -$10.01M | -$22.46M |
| EBITDA | -$6.73M | -$16.91M |
| EPS (Diluted) | -$0.31 | -$0.83 |
Margins
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Gross Margin | 2954.7% | 52.9% |
| Operating Margin | -4059.4% | -44.0% |
| Profit Margin | -5885.3% | -40.2% |
| EBITDA Margin | -3960.6% | -30.2% |
Returns
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Return on Assets (ROA) | -213.6% | -40.9% |
Growth
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -65.3% | 2.25% |
| Revenue Growth (5Y CAGR) | -40.6% | 6.48% |
Balance sheet
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $477.00K | $61.43M |
| Total Debt | $1.71M | $118.52M |
| Net Cash (Debt) | -$1.23M | $15.35M |
| Net Cash Per Share | -$0.03 | $0.66 |
| Equity (Book Value) | -$7.26M | $49.09M |
| Book Value Per Share | -$0.16 | $1.37 |
| Tangible Book Value | -$7.50M | $23.52M |
| Working Capital | -$2.54M | $76.81M |
Financial position
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Current Ratio | 0.52 | 3.34 |
| Quick Ratio | 0.37 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.56M | -$12.35M |
Efficiency
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.39 |
| Inventory Turnover | 13.98 | 2.70 |
| Revenue Per Employee | $4.72K | $404.87K |
| Profits Per Employee | -$277.92K | -$703.34K |
| Employee Count | 36 | 74 |
Dividends and yields
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Earnings Yield | -95.8% | -23.3% |
Shares
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Shares Outstanding | 46,633,700 | 58,127,000 |
| Shares Change (YoY) | 89.5% | 10.9% |
| Shares Change (QoQ) | 7.20% | 0.54% |
| Float | 40,669,400 | 49,136,700 |
| Shares Held by Insiders | 12.8% | 11.6% |
Scores
| Measure | Aspira Women's Health | Industry median |
|---|---|---|
| Altman Z-Score | -177.58 | -0.22 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | 123.66 | -2.62 |
Calculated by StockData from Aspira Women's Health's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.